Positive AVISE (n=20) | Non-positive AVISE (n=97) | P value | |
Demographics | |||
Women | 95.0 | 93.8 | ns |
Average age at baseline | 52.7±12.1 | 53.9±14.7 | ns |
Baseline diagnoses at t=0% (n) | |||
SLE | 0 (0) | 0 (0) | ns for all |
RA | 15.0 (3) | 22.7 (22) | |
UCTD | 65.0 (13) | 35.1 (34) | |
Other autoimmune | 10.0 (2) | 23.7 (23) | |
Non-inflammatory (OA) | 10.0 (2) | 6.2 (6) | |
FM without CTD | 0 (0) | 9.3 (9) | |
Discoid lupus without SLE | 0 (0) | 2.1 (2) | |
Unclear | 0 (0) | 1.0 (1) | |
Medications at t=0 (%) | ns for all | ||
Hydroxychloroquine | 65.0 (13) | 49.5 (48) | |
Methotrexate | 15.0 (3) | 7.2 (7) | |
Mycophenolate | 0.0 | 0.0 | |
Azathioprine | 5.0 (1) | 5.2 (5) | |
Other DMARDs (leflunomide and sulfasalazine) | 5.0 (1) | 4.1 (4) | |
Belimumab | 5.0 (1) | 4.1 (4) | |
RA biologic | 5.0 (1) | 16.5 (16) | |
Medications at t=2 (%) | |||
Corticosteroids | 10.0 (2) | 9.3 (9) | ns |
Hydroxychloroquine | 65.0 (13) | 49.4 (48) | ns |
Methotrexate | 0 (0) | 6.3 (6) | ns |
Mycophenolate | 15.0 (3) | 0 (0) | 0.005 |
Azathioprine | 5.0 (1) | 1.0 (1) | ns |
Other DMARDs (leflunomide and sulfasalazine) | 0 (0) | 11.3 (4) | ns |
Belimumab | 0 (0) | 4.1 (4) | ns |
Change in diagnosis at t=2 | 80.0 (16) | 28.9 (28) | <0.0001 |
CTD, connective tissue disease; DMARD, disease-modifying antirheumatic drug; FM, fibromyalgia ; ns, not significant; OA, osteoarthritis; RA, rheumatoid arthritis; UCTD, undifferentiated connective tissue disease.